HHV8 ORF K14 Polyclonal Antibody, PE-Cy7 Conjugated
Product Specifications
Background
HHV8 has been found to be associated with three different diseases observed in AIDS patients; kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.
Synonyms
NULL
Host
Rabbit
Cross Reactivity
Virus
Immunogen
111-210/348
Target
HHV8 ORF K14
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy7
Source
KLH conjugated synthetic peptide derived from human HHV8/ORF K14
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/780nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Cross Reactivity Details
HHV 8 type M
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470009-500 1x 500 µL
MART-1 / Melan-A (M2-7C10), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941037-100 1x 100 µL
CD44 Standard (DF1485), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882350-100 1x 100 µL
GPN1 / XAB1 (DNA Repair & Protein Synthesis) (GPN1/2350), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472968-100 1x 100 µL
EGFR (Epidermal Growth Factor Receptor) (GFR/2968R), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details